Evidence map›Paper›PMID 24839953›Full record

ArticleCancer2014

Coexpression of CD44-positive/CD133-positive cancer stem cells and CD204-positive tumor-associated macrophages is a predictor of survival in pancreatic ductal adenocarcinoma.

Ya-Chin Hou, Ying-Jui Chao, Hui-Ling Tung, Hao-Chen Wang, Yan-Shen Shan

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 2 pooled it
6.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 2 syntheses or guidelines pooled it, 101 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Review
  7. Cancer Stem Cells in Pancreatic Ductal Adenocarcinoma.International journal of molecular sciences · 2023
    Review
  8. Article
  9. Review
  10. Review
  11. microRNA-21 Regulates Stemness in Pancreatic Ductal Adenocarcinoma Cells.International journal of molecular sciences · 2022
    Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Ya-Chin HouInstitute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Ying-Jui Chao
Hui-Ling Tung
Hao-Chen Wang
Yan-Shen Shan
National Cheng Kung University Hospital · TWNational Cheng Kung University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe interactions between cancer stem cells (CSCs) and tumor-associated macrophages (TAMs) can promote tumor progression, maintain the CSCs population, and reduce therapeutic effects. The objective of this study was to investigate the coexpression of CSCs and TAMs and its clinical significance in pancreatic ductal adenocarcinoma (PDAC).

methodsNinety-six patients with PDAC were included in this study. Tissue microarrays were constructed for immunostaining of the CSCs markers CD44 and CD133 and the TAMs marker CD204. Correlations between the expression of CSCs and TAMs markers and clinicopathologic characteristics or disease progression were analyzed.

resultsExpression levels of CD44/CD133 and CD204 were significantly higher in tumor tissues than in normal tissues (P < .0001). The variables associated with survival were high coexpression of CD44/CD133 (P = .000), high expression of CD204 (P = .011), and tumor grade (P = .014). There was a positive correlation between CD44/CD133 and CD204 expression (r = 0.294; P = .004). Survival analysis indicated that high coexpression of CD44/CD133 and CD204 was associated significantly with shorter overall survival (P = .000) and disease-free survival (P = .003). Multivariate analysis revealed that high CD44/CD133 expression was an independent prognostic factor for disease-free survival, whereas high CD204 expression was an independent predictor for both overall and disease-free survival.

conclusionsCoexpression of CD44/CD133 and CD204 is a useful survival prediction marker for patients with PDAC.

Indexed as

AC133 AntigenAntigens, CDBiomarkers, TumorCarcinoma, Pancreatic DuctalCell CommunicationDisease-Free SurvivalFemaleGlycoproteinsHumansHyaluronan ReceptorsKaplan-Meier EstimateMacrophagesMaleNeoplastic Stem CellsPancreatic NeoplasmsPeptidesAC133 AntigenAntigens, CDBiomarkers, TumorCD44 protein, humanGlycoproteinsHyaluronan ReceptorsMSR1 protein, humanPeptidesPROM1 protein, humanScavenger Receptors, Class Acancer stem cellsCD133CD204CD44pancreatic ductal adenocarcinomatissue microarraystumor-associated macrophages

Identifiers

PMID24839953
PMCPMC4232049
OpenAlexW1684009664

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.